Peginterferon Alfa-2A

證據等級: L5

預測適應症: 10 個

Peginterferon Alfa-2a: From Chronic Hepatitis C to Hepatitis B Virus Infection

One-Sentence Summary

Peginterferon alfa-2a is the pegylated interferon best known as Pegasys, with chronic hepatitis C as its foundational, globally established use. The TxGNN model's top prediction for this drug is Hepatitis B Virus Infection, an indication supported by 50 clinical trials and 20 publications — though as detailed below, this is best understood as a confirmation of an already-approved use rather than a genuinely novel repurposing signal.

Quick Overview

Item	Content
Original Indication	Chronic Hepatitis C (established international indication; not currently licensed in this jurisdiction)
Predicted New Indication	Hepatitis B Virus Infection
TxGNN Prediction Score	99.94%
Evidence Level	L1
Norway Market Status	Not Marketed
Number of Authorizations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Detailed mechanism-of-action data was not available from the standard drug reference (DG002, data gap). However, the evidence pack's own repurposing rationale supplies the key mechanistic detail: peginterferon alfa-2a is an already-approved treatment for chronic hepatitis B (marketed as Pegasys), working by inducing interferon-stimulated gene expression and enhancing host immune clearance of HBV. This is the same broad antiviral/immunomodulatory mechanism that underlies its long-standing role as standard-of-care therapy for chronic hepatitis C, as reflected throughout the clinical trial evidence below (e.g., "the current standard of care in HCV patients consists of a combination of peg-IFN alpha and ribavirin").

Because both chronic hepatitis B and chronic hepatitis C are viral, hepatotropic infections responsive to type-I interferon signaling, the mechanistic bridge between the two is well established rather than speculative. Importantly, the evidence pack itself flags that this particular signal — HBV infection — is not a novel indication but an existing, on-label use ("MOA明確且非新適應症，屬既有標籤內用途"). In other words, TxGNN has correctly recovered a known therapeutic relationship rather than surfaced a new hypothesis. This should be read as a validation of the model's reliability on this drug, and it also means the extensive trial base below reflects decades of confirmatory research rather than early-stage exploratory signal.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT01937728	Phase 4	Completed	542	Tailored (individualized) duration regimens with peginterferon alfa-2a plus ribavirin, guided by viral kinetics
NCT00436163	Phase 4	Completed	39	Baltic post-marketing study: efficacy/safety of peginterferon alfa-2a 180 mcg weekly in HBeAg-positive CHB, treatment-naive
NCT01706575	Phase 2	Completed	76	Adding Pegasys to nucleos(t)ide analogue therapy in HBeAg-negative genotype D CHB with stable HBV DNA suppression
NCT00435825	Phase 4	Completed	551	4-arm RCT comparing 24 vs 48 weeks and 90 vs 180 mcg PEGASYS doses for HBeAg seroconversion and safety
NCT01011738	N/A	Completed	1842	Large multicenter observational cohort evaluating on-treatment predictors of response to Pegasys in HBeAg+/- CHB
NCT02604823	Phase 4	Completed	307	Efficacy and safety of Pegasys in naive, interferon- or lamivudine-pretreated HBeAg-positive CHB patients
NCT01730508	N/A	Completed	978	Multicenter observational cohort in Chinese HBeAg-negative CHB patients receiving Pegasys per local label
NCT00940485	Phase 4	Completed	200	Combination/sequential peginterferon alfa-2a plus entecavir for optimizing HBeAg seroconversion
NCT01086085	Phase 4	Completed	265	Response-guided treatment (RGT) optimization of PEGASYS in HBeAg-positive CHB
NCT03210506	N/A	Unknown	120	Mechanistic study of cytokine changes during peginterferon alfa-2a and nucleoside analogue therapy, supporting immune-regulatory MOA

Literature Evidence

PMID	Year	Type	Journal	Key Findings
15987917	2005	RCT	N Engl J Med	Pivotal registration trial: peginterferon alfa-2a ± lamivudine for HBeAg-positive chronic hepatitis B
30318613	2019	RCT	Hepatology	Entecavir/peginterferon alfa-2a combination in HBeAg-positive immune-tolerant children with CHB
30549279	2019	RCT	Hepatology	Entecavir and peginterferon alfa-2a in adults with immune-tolerant chronic HBV infection
30865588	2019	Systematic Review/Meta-analysis	Antiviral Therapy	Individual participant data meta-analysis establishing peginterferon alfa-2a treatment stopping rules in CHB
29715359	2018	Review	JAMA	Comprehensive review of chronic hepatitis B infection and treatment landscape
21423260	2011	Review	Nat Rev Gastroenterol Hepatol	Overview of hepatitis B therapy, including interferon-based approaches
18220290	2008	RCT (Phase 3 registration data)	Hepatology	HBeAg and HBV DNA as outcome predictors during peginterferon alfa-2a therapy (n=271, large multinational trial)
33720089	2021	RCT	J Pediatr Gastroenterol Nutr	Peginterferon alfa-2a plus lamivudine or entecavir in children with immune-tolerant CHB
26700861	2015	RCT	Virology Journal	Double-blind randomized trial of long-term peginterferon alfa-2a effects in Japanese CHB patients
33339708	2021	Cohort	J Formos Med Assoc	Virological/immunological predictors of long-term outcomes of peginterferon alfa-2a in HBeAg-negative CHB

Norway Market Information

No authorizations are currently registered for this drug in this jurisdiction (market status: Not Marketed, total licenses: 0). All clinical and literature evidence above reflects use of the product (marketed internationally as Pegasys) in other jurisdictions.

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: The evidence base for peginterferon alfa-2a in hepatitis B virus infection is exceptionally strong (L1 — multiple completed Phase 3/4 RCTs plus a systematic review/meta-analysis), but this reflects an already-established, on-label indication rather than a novel repurposing discovery, and the drug currently has no local market authorization.

To proceed, the following is needed:

Confirm local (TFDA-equivalent) label status and obtain the official package insert for warnings/contraindications (DG001)
Obtain formal MOA documentation from DrugBank or manufacturer labeling (DG002)
Clarify regulatory pathway for market authorization given current "Not Marketed" status
Given that this signal is a known indication rather than a new discovery, consider redirecting repurposing-focused review effort toward lower-ranked, evidence-poor candidates in this pack (e.g., hepatitis E virus infection, L3) where genuine novelty assessment is more relevant
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.